TABLE 1.
Characteristics of evaluable plazomicin-treated patientsa
| Participant characteristics (n = 281) | Value |
|---|---|
| Female sex, n (%) | 157 (55.9) |
| Infection type | |
| cUTI, n (%) | 169 (60.1) |
| AP, n (%) | 112 (39.9) |
| Age (years), mean (SD) | 58 (18) |
| Total body weight (kg), mean (SD) | 76 (16) |
| CLcr (ml/min)b , median (IQR) | 77.4 (55.4–95.5) |
| CLcr, n (%) | |
| ≥60 ml/min | 189 (67.3) |
| 59–31 ml/min | 92 (32.7) |
| Plazomicin dose (mg), median (IQR) | 960 (770–1,120) |
| Any rise in Scr ≥0.5 mg/dl, n (%) | 17 (6.0) |
a
CLcr obtained on day of plazomicin concentration sampling.
b
AP, acute pyelonephritis; SD, standard deviation; IQR, interquartile range; Scr, serum creatinine.